The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults

M. R. Litzow, A. K. Fielding, S. M. Luger, E. Paietta, Y. Ofran, J. M. Rowe, A. H. Goldstone, M. S. Tallman, H. M. Lazarus

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations

Abstract

The introduction of the tyrosine kinase inhibitors (TKI) into the treatment of patients with Ph or BCR-ABL1-positive acute lymphoblastic leukemia has revolutionized the treatment of this poor prognosis acute leukemia. The combination of TKI with chemotherapy has improved response rates and allowed more patients to proceed to allogeneic hematopoietic cell transplant (alloHCT). Older patients have excellent responses to TKI and corticosteroids or in combination with minimal chemotherapy. This raises the question as to whether patients require full-intensity chemotherapy with TKI to achieve molecular remissions. The pediatricians have proposed that cure is achievable without alloHCT in children. These results have suggested that many patients may not require traditional chemotherapy in addition to TKI to achieve remission, and that patients who achieve a negative minimal residual disease state may not require alloHCT. The data in support of these questions is presented here and a suggested future clinical trial design based on these data is proposed.

Original languageEnglish (US)
Pages (from-to)1592-1598
Number of pages7
JournalBone Marrow Transplantation
Volume52
Issue number12
DOIs
StatePublished - Dec 1 2017

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint

Dive into the research topics of 'The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults'. Together they form a unique fingerprint.

Cite this